European governments scramble to interpret Trump's new drug pricing order

In the U.S., drug prices are shaped by complex negotiations involving pharmacy benefit managers that act as middlemen between drugmakers and employer clients and health insurers and have been criticised for inflating costs. In Europe, countries generally have public health systems that negotiate directly with manufacturers and keep costs down.

/.../

Trump said if drugmakers do not cut prices they could be hit with tariffs.